News

GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...
Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its blockbuster semaglutide (GLP-1 RA)-based therapies, Wegovy for obesity and ...
GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...
Endocrinologist Dr Ambrish Mithal, the author of the recently-released book, The Weight Loss Revolution, talks to fitness and ...
Endocrinologist Dr Ambrish Mithal, the author of the recently-released book, The Weight Loss Revolution, talks to fitness and ...
Major insurance changes are coming to GLP-1 drugs for weight loss. Here’s how that could affect patients By CNN Newsource Published July 1, 2025 5:00 AM ...
Canadian study reveals diabetic patients taking GLP-1 medications face twice the risk of eye problems, with longer exposure increasing danger of macular degeneration.
Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 liver disease study.
Earwax may provide an unexpected early warning of Parkinson’s disease (PD), according to new research.
Parkinson's Disease is the second most common neurodegenerative disease after Alzheimer's and a New Hampshire man is making sure that those facing a diagnosis are getting the support they need.
Major insurance changes are coming to GLP-1 drugs for weight loss. Here’s how that could affect patients Shelby Knowles/Bloomberg/Getty Images via CNN Newsource ...